Nevisense – AI-Powered Technology for More Accurate Melanoma Detection
Nevisense is the world’s first objective diagnostic support tool for the non-visual detection of malignant melanoma. By collectingCollecting and analyzing precise electrical measurements from the epidermis and dermis, it provides reliable, actionable information that no other method can offer. With just one straightforward procedure, Nevisense enables healthcare providers to objectively assess suspicious lesions before excision, improving diagnostic confidence.
The Diagnostic Challenge
Most dermatologists feel confident with today’s methods of visual examination. Literature shows, however, that the accuracy of clinical diagnosis of cutaneous melanoma with or without dermoscopy is far from 100
%. This uncertainty has significant consequences. On one hand, life-threatening melanomas may be missed. On the other hand, benign lesions are often unnecessarily excised as a precaution. Nevisense addresses this challenge by supplementing the examination process with reliable, objective data, leading to more confident and accurate diagnoses.
The Nevisense Solution
With Nevisense, SciBase has developed an innovative solution to improve the accuracy of malignant melanoma detection. Using Electrical Impedance Spectroscopy (EIS), which applies a harmless electrical signal to the skin, Nevisense provides a reliable and objective analysis of suspicious lesions. This complements a physician’s standard clinical evaluations, adding valuable diagnostic insights.
The Nevisense method is both safe and painless. It delivers critical diagnostic information that is otherwise unavailable through traditional methods, helping physicians make more informed decisions in difficult or borderline cases. By using Nevisense as a diagnostic support tool, clinicians can significantly enhance diagnostic accuracy, leading to the early detection of malignant melanoma and a reduction in unnecessary biopsies.
Intended Use
Nevisense EIS functionality is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma. Nevisense is designed to be used to obtain additional information prior to decision about most appropriate action for the patient. Nevisense should not be used to confirm a clinical diagnosis of melanoma.
Nevisense EIS functionality is only for use by medical professional trained in the clinical diagnosis of skin cancer. The Nevisense result is one element of the overall clinical assessment. The output of Nevisense should be used in combination with clinical and historical signs of melanoma to obtain additional information prior to decision about most appropriate action.
The system is also intended to use for research purposes in general measurement of electrical impedance of the skin. The research measurements could be made with non invasive as well with micro invasive (spike) electrodes.
The Nevisense procedure integrates seamlessly into physicians’ normal patient flow. Unlike pathology, which can take time to deliver results, Nevisense provides immediate diagnostic information at the point of care, allowing for quicker, more informed decisions.
The Nevisense procedure fits easily within physicians’ normal patient flow. Compared with pathology which can take time to provide results, Nevisense provides diagnostic information to the physician at point-of-care.